Deliver a robust portfolio of drug discovery hit and lead series for leishmaniasis
current phase of drug development
updated 1 Jun 2021
To identify new hit series that could be progressed and become new drug candidates for visceral leishmaniasis, DNDi tests chemical compounds for in vitro activity against L. donovani. Collections of natural and synthetic compounds are typically accessed through partners and commercial suppliers, and high-throughput screening is conducted in collaboration with University of Dundee and Institut Pasteur Korea.
In 2015, to complement bilateral collaborations for screening and lead optimization, DNDi launched the NTD Drug Discovery Booster with several major pharmaceutical companies.
Get our latest news, personal stories, research articles, and job opportunities.